Biolife4d, of Chicago, filed a $50 million IPO with the SEC under Regulation A+ rules, allowing individual investors help crowdfund its cardiac tissue regeneration and organ replacement process. The company is seeking to leverage advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant. Proceeds will be used to bolster working capital and fund key corporate initiatives, including hiring additional employees, procuring laboratory space and developing and licensing related technology.